Weight Loss Clinic - Mounjaro
Transform into a healthier, fitter version of yourself with our weight loss clinic. We provide personalized services tailored to your specific needs and health requirements.
Mounjaro
Mounjaro is the brand name of the medication Tirzepatide, licensed for the treatment of Weight Management (weight loss and weight maintenance) and Type 2 diabetes. It is the latest and most effective weight loss drug, which was launched in February 2024.
It mimics the action of one of your body’s naturally occurring incretin hormones – GLP-1 and GIP (the first of its kind) released after food intake. These regulate appetite, feeling of fullness, and blood glucose levels. Mounjaro is the first weight loss injection in its class that works by regulating blood glucose levels, satiety, and hunger.
Indication
To reduce weight in obese patients with an initial Body Mass Index (BMI) of ≥ 30 kg/m2 or overweight patients with BMI ≥27 kg/m2 to <30kg/m2 and weight-related comorbidities.
Inclusion Criteria
Valid consent has been obtained from the patient/carer who does not want to consult with their GP and would prefer to access treatment from the PGD user.
- Patients aged between 18 and 74 years.
- Patients with an initial BMI of 30 kg/m2 or greater.
- Patients in which a supervised diet, behaviour modification and increasing physical activity failed to achieve a realistic reduction in weight.
- Patients with an initial BMI of 27 kg/m2 or greater with at least one weight-related comorbidity, including but not limited to:
- Hypertension
- Dyslipidaemia
- Obstructive sleep apnoea
- Type 2 diabetes mellitus
Healthcare professionals must be able to justify the decision to supply Wegovy to patients with a BMI ≥27 kg/m2 to <30kg/m². The patient must have a health condition that is either caused or exacerbated by their weight, and that is likely to be either resolved or improved by weight loss.